文献速递免疫规划传染病防控与疫情报告

尼泊尔儿童单剂Vi-TT结合疫苗8年保护效果:TyVOID前瞻性队列随访

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.
PubMed 文献 · Lancet Glob Health · 2026-08-10

TyVOID研究对尼泊尔TyVAC随机对照试验中的儿童进行前瞻性队列随访,评估单剂Vi-TT结合疫苗至8年的保护效果。结果显示,接种后1-5年疫苗有效性为77%,4-8年降至53%,提示保护力随时间衰减。研究支持考虑为学龄儿童接种加强针以维持保护。

要点

  • 单剂Vi-TT在接种后1-5年疫苗有效性为77%,4-8年降至53%。
  • 2017-18队列伤寒发病率为111/10万人年,2020-21队列为46/10万人年。
  • 研究提示保护力随时间的推移而衰减,可考虑加强免疫。

核心结论

  • 单剂Vi-TT在尼泊尔儿童中接种后前4年提供强保护,至8年时保护力出现衰减证据。

研究设计与样本

  • TyVOID为前瞻性队列研究,延伸了尼泊尔Lalitpur的3期双盲随机对照试验(TyVAC)的随访。

临床怎么用

  • 研究结果支持考虑为学龄儿童接种加强针以维持对伤寒的保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In low-income and middle-income countries, where typhoid fever remains a major public health problem, WHO recommends the use of typhoid conjugate vaccine (TCV). Here, we report vaccine effectiveness up to 8 years following a single dose of TCV in Nepal. METHODS: TyVOID was a prospective cohort study that extended the follow-up of children enrolled in a phase 3, double-blind, randomised controlled trial in Lalitpur, Nepal (TyVAC; Nov 20, 2017, to Oct 20, 2021). Children aged 9 months to 15 years were randomly assigned (1:1) to receive Vi-tetanus toxoid conjugate vaccine (Vi-TT) or a capsular group A meningococcal conjugate (MenA) vaccine. After unmasking and crossover vaccination, our study followed the trial participants until Oct 31, 2025. TyVAC participants who received Vi-TT were eligible for this study and categorised into either the 2017-18 cohort or 2020-21 cohort, depending on when they received the Vi-TT vaccine. The primary outcome, which was assessed in children who received both Vi-TT and MenA vaccines and with known TCV vaccination status during the government catch-up campaign in 2022, was the incidence of blood culture-confirmed typhoid identified through facility-based passive surveillance and medical record review. Adjusted incidence rate ratios (IRRs) were estimated using Poisson regression adjusted for age and sex. Vaccine effectiveness at 1-5 years and 4-8 years post-vaccination was estimated using a test-negative design among febrile children presenting to surveillance clinics, comparing odds of Vi-TT vaccination between culture-confirmed typhoid cases with negative controls. FINDINGS: 16 131 TyVAC participants were enrolled at TyVOID baseline, of whom 14 850 provided information on Vi-CRM197 vaccination during the government catch-up campaign. After crossover and unmasking, the primary analysis population included 4941 participants vaccinated with Vi-TT in 2017-18 and 4856 participants vaccinated with Vi-TT in 2020-21. In 4856 participants in the 2020-21 Vi-TT cohort, 2402 (49·5%) were female, 2454 (50·5%) were male, and the median age at Vi-TT vaccination was 10·4 years (IQR 7·3-13·7). In 4941 participants in the 2017-18 Vi-TT cohort, 2482 (50·2%) were female, 2459 (49·8%) were male, and the median age at Vi-TT vaccination was 7·7 years (IQR 4·5-11·0). During a median follow-up of 3·7 years (3·7-3·8), the typhoid incidence rate was 111 per 100 000 person-years (95% CI 64-177) in the 2017-18 cohort and 46 per 100 000 person-years (18-94) in the 2020-21 cohort (adjusted IRR 2·41 [95% CI 1·00-5·80]; one-sided p=0·025). Vaccine effectiveness was 77% (95% CI 46-90; p=0·0006) in the 2020-21 Vi-TT cohort (1-5 years after vaccination), and 53% (8-76; p=0·027) in the 2017-18 Vi-TT cohort (4-8 years after vaccination). INTERPRETATION: A single Vi-TT dose confers strong protection in the first 4 years among Nepali children, with evidence of waning by 8 years. These findings support consideration of a booster dose to sustain protection in school-age children who remain at high risk of typhoid fever. FUNDING: Gates Foundation and Wellcome Trust.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Pant D, Zhang Y, Basile FW, et al. 8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial. Lancet Glob Health. 2026. PMID: 42575113. doi:10.1016/j.langlo.2026.104009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。